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Background: The presence of disseminated tumor cells (DTC) in bone marrow (BM) of breast cancer patients is
associated with reduced clinical outcome. Bisphosphonate treatment was shown to eradicate DTC from BM in several
studies. This controlled randomized open-label multi-center study aimed to investigate the influence of zoledronic acid
(ZOL) on DTC and survival of breast cancer patients (Clinical Trial Registration Number: NCT00172068).
Methods: Patients with primary breast cancer and DTC-positive bone marrow were randomized to treatment with ZOL
plus adjuvant systemic therapy (n = 40) or adjuvant systemic therapy alone (n = 46) between 03/2002 and 12/2004. DTC
were identified by immunocytochemistry using the pancytokeratin antibody A45B/B3 and by cytomorphology. The
change in DTC numbers at 12 months and 24 months versus baseline, as well as patient outcomes were evaluated.
Results: 86 patients could be included into survival analysis (median follow-up: 88 months, range: 8–108 mths). Patients
in the control group were more likely to die during follow-up than those in the ZOL-group (11% vs. 2%, p = 0.106). 15%
of patients in the control group presented with relapse whereas only 8% of ZOL group patients developed metastatic or
recurrent disease during follow-up (p = 0.205). At 24 months, 16% of patients from the control group were still DTC
positive, whereas all patients treated with ZOL became DTC negative (p = 0.032). Patients presenting with persistent DTC
12 months after diagnosis had significantly shorter overall survival (p = 0.011).
Conclusions: Bisphosphonate therapy contributes to eradication of disseminated tumor cells. The positive influence of
bisphosphonates on survival in the adjuvant setting may be due to their effects on DTC.
Trial registration: ClinicalTrials.gov Identifier: NCT00172068 [Zoledronic Acid in the Treatment of Breast Cancer With
Minimal Residual Disease in the Bone Marrow (MRD-1)].
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The presence of disseminated tumor cells (DTC) in bone
marrow (BM) is a common phenomenon observed in
30-40% of primary breast cancer patients. As demon-
strated by a large, pooled analysis of BM specimens from
more than 4,700 patients, DTC presence at the time of
diagnosis is an independent prognostic factor [1]. In
addition, it has been shown that tumor cells are able to* Correspondence: tanja.fehm@t-online.de
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reproduction in any medium, provided the orsurvive chemotherapy [2] and that their persistence is
strongly associated with poor outcome [3]. Therefore, al-
ternative therapeutic options that improve elimination of
DTC may reduce the risk of relapse and improve sur-
vival in early breast cancer patients.
Recently, two large randomized clinical trials demon-
strated zoledronic acid (ZOL) to significantly prolong
disease-free survival in breast cancer patients undergo-
ing adjuvant hormonal therapy (ABCSG-12, ZO-FAST).
In contrast to these two trials, interim analysis from the
AZURE trial did not show a benefit from adding ZOL to
adjuvant therapy in the overall patient population [4].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ZOL significantly improved survival in patients who
were more than 5 years postmenopausal [5,6]. It has been
hypothesized that anticancer effects of bisphosphonates
(BP) may occur through elimination of DTC from the
bone marrow; potential indirect mechanisms of ZOL-
mediated activity involve a series of microenvironmental
changes, such as angiogenesis inhibition, activation of im-
mune responses, and interactions with mesenchymal stem
cells [7-9]. However, limited data are available on the
in vivo effects of ZOL on DTC.
The aim of the present randomized controlled trial
was to evaluate the influence of zoledronic acid on 1)
DTC presence after 12 and 24 months of treatment and
2) disease-free and overall survival.
Methods
Patients
In total, 96 patients with primary breast cancer were in-
cluded into this prospective open-label parallel-group
study between 2002 – 2004 at four study centers in
Germany. All patients presented with minimal residual
disease composed of disseminated tumor cells (DTC) in
bone marrow at the time of primary surgery and were to
receive adjuvant therapy (hormonal, cytotoxic, or both).
Exclusion criteria were inflammatory, metastatic, or re-
current breast cancer, creatinine clearance < 30 ml/min,
current active dental problems or trauma, or a current
or prior diagnosis of osteonecrosis of the jaw (ONJ).
Neoadjuvant chemotherapy was not permitted. All pa-
tients provided written informed consent prior to initi-
ation of any study-specific procedures. The study was
approved by the Ethics Committee at all participating in-
stitutions (University of Tuebingen, Hannover Medical
School, University of Munich, Klinikum Bielefeld). This
clinical study was designed, implemented, and reported
in accordance with the international Good Clinical Prac-
tice Guidelines with applicable local regulations.
Patients were prospectively stratified on the basis of 6
predefined strata: 2 nodal-status categories (positive,
negative) by 3 adjuvant-treatment categories (chemo-
therapy, hormonal therapy, chemotherapy plus hormo-
nal therapy). Patients were then randomized 1:1 to
adjuvant therapy alone (control) or with intravenous
zoledronic acid every 4 weeks for 24 months. Per the ap-
proved label, zoledronic acid dosing was guided by cre-
atinine clearance.
The primary endpoint was the effect of ZOL on DTC
counts after 12 months. Secondary endpoints at 24
months included safety; changes in DTC counts versus
baseline; bone-metastasis–free survival, which included
death from any cause or bone metastasis; and disease-
free survival, which included death from any cause or
disease recurrence at any site. Correlative analyses ofchange in DTC counts with TNM-stage, estrogen- and
progesterone-receptor status, and menopause status were
planned.
Detection of disseminated tumor cells in bone marrow
Bone marrow aspirates for DTC assessment were obtained
directly before primary breast cancer surgery in all pa-
tients. In 71 and 59 cases an additional BM aspiration was
conducted 12 months and 24 months after diagnosis, re-
spectively. DTC detection was performed as described in
detail previously [10]. 10 to 20 ml bone marrow (BM) was
aspirated from the iliac crest into syringes containing
heparin anticoagulant under general anesthesia using
Jamshidi’s technique. Tumor cell isolation and detec-
tion was performed based on the recommendations for
standardized tumor cell detection [11]. Samples were
separated by density centrifugation using Ficoll (dens-
ity 1,077 g/ml, Biochrom, Germany). Mononuclear
cells were collected from the interphase layer and were
spun down onto a glass slide (Hettich cytocentrifuge,
Germany) (106 MNC/spot). For detection of cytokeratin-
positive (CK) tumor cells, slides were fixed in 4% neutral
buffered formalin for 10 minutes and rinsed in PBS. Auto-
matic immunostaining was performed on the DAKO
Autostainer using the monoclonal mouse A45-B/B3 anti-
body (Micromet, Germany) and the DAKO-APAAP de-
tection kit (DakoCytomation, Denmark) according to the
manufacturer’s instructions. The A45-B/B3 antibody is di-
rected against common cytokeratin epitopes including the
CK heterodimers 8/18 and 8/19. The malignant breast cell
line MCF-7 was used as a positive control. For each pa-
tient 2 × 106 cells were analyzed on two slides. Analysis
was performed on the Automated Cellular Imaging Sys-
tem (ACIS, ChromaVision Medical Systems, San Juan,
Capistrano, CA).
Survival analysis
Follow-up data was obtained from the Cancer Registry
of the University of Tuebingen, Germany. For 86 pa-
tients a follow-up could be obtained (ten patients were
lost to follow-up). Survival analysis was performed by
Kaplan–Meier-method. Statistical analysis was performed
using SPSS (Version 16) considering p-values less than
0.05 to be statistically significant. Survival intervals were
measured from the time of BM aspiration to the time of
death or of the first diagnosis of relapse. Relapse was de-
fined as either local recurrence or distant metastasis.
Results
Patients’ characteristics
A total of 96 patients were enrolled in the study.
Cytokeratin-positive DTC were detected at diagnosis
in bone marrow specimens from all patients. The number
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cells.
Patients’ characteristics of all patients were presented
previously by Solomayer et al. [12]. In this manuscript
we focus on survival analysis. For ten patients no follow-
up could be obtained; these patients are censored as lost
to follow-up. For 86 patients a follow-up of at least 8
months was available. 64 per cent of these patients had
T1 tumors and 88% were node negative. 40 out of 86 pa-
tients were assigned to receive adjuvant therapy plus
intravenous zoledronic acid every 4 weeks. 46 patients
were randomized into control group (adjuvant therapy
alone). Clinical data are shown in detail in Table 1. The
distribution of patients is summarized in a Recommenda-
tions for Tumor Marker Prognostic Studies (REMARK)
diagram [13] (Figure 1).
Survival analysis
86 patients could be included into the survival analysis.
The median follow-up of patients was 88 months (range:





Total 86 40 46
Menopausal status
Premenopausal 55 14 (35%) 17 (37%)
Postmenopausal 31 26 (65%) 29 (63%)
Tumor size
pT1 51 26 (67%) 25 (61%)
pT2-3 29 13 (33%) 16 (39%)
Nodal status
Negative 70 35 (90%) 35 (85%)
Positive 10 4 (10%) 6 (15%)
Grading
I/II 68 33 (87%) 35 (88%)
III 10 5 (13%) 5 (12%)
ER status
Negative 9 5 (14%) 4 (12%)
Positive 60 30 (86%) 30 (88%)
PR status
Negative 22 11 (31%) 11 (32%)
Positive 47 24 (69%) 23 (68%)
HER2 status
Negative 58 30 (86%) 28 (85%)
Positive 10 5 (14%) 5 (15%)
DTC counts at diagnosis
Median [range]
2 [1-6] 2 [1-35]
Abbreviations: BM bone marrow, DTC disseminated tumor cells, ER estrogen
receptor, PR progesterone receptor.period. Ten patients (12%) suffered from relapse during
follow-up. Eight patients presented with metastatic
spread to distant site (three in combination with local
recurrence). Two patients were diagnosed with local
recurrence only. Data on clinical outcome are summa-
rized in Table 2.
Patients who received adjuvant therapy alone (control
group) were more likely to die during follow-up than
those who received adjuvant therapy plus zoledronic
acid (11% vs. 2%, p = 0.106). In addition 15% of patients
in the control group presented with relapse whereas only
8% of ZOL group patients developed metastatic or re-
current disease during follow-up (p = 0.205). These dif-
ferences did not reach statistic significance due to small
sample size. However, a trend toward shorter overall and
disease-free survival in the control group was observed.
Kaplan-Meier survival curves are presented in Figure 2.
Persistent disseminated tumor cells at 12 months
In 71 cases, a second bone marrow aspiration was
performed 12 months after diagnosis. Persistent DTC
were detected in 14 out of 71 patients (20%; Table 3). In
the ZOL group only four patients were BM positive at
12 months whereas ten patients from the control group
failed to clear DTC from their BM (p = 0.106). Patients
presenting with persistent DTC 12 months after diagno-
sis had significantly shorter overall survival (p = 0.011,
Figure 3), while disease-free survival remained similar.
Persistent DTC at 24 months
A third bone marrow sample 24 months after diagnosis
was obtained in 59 patients. In the control group 5 out
of 32 patients (16%) were DTC positive. All patients
treated with ZOL became DTC negative 24 months after
diagnosis (p = 0.032; Table 3). DTC persistence at 24
months did not correlate with survival. Figure 4 illus-
trates changes of DTC status in both arms at 12 and
24 months.
Discussion
This is the first prospective, randomized, controlled
study evaluating the influence of zoledronic acid on
DTC presence and survival in early-stage breast cancer
patients. Our results demonstrate that bisphosphonate
therapy contributes to eradication of disseminated tumor
cells. All patients treated with ZOL became bone mar-
row negative after 24 months in comparison to 84% in
the control group (p = 0.032). This is in accordance with
previous studies; Aft et al. reported that ZOL adminis-
tered with neoadjuvant chemotherapy resulted in a de-
creased proportion of DTC-positive patients. This effect
did not reach statistic significance (p = 0.054); however,
in contrast to our study the reevaluation of bone mar-
row status was performed after a relatively short time
Figure 1 Patient distribution diagram according to the Recommendations for Tumor Marker Prognostic Studies (REMARK).
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the present study no significant correlation between
bisphosphonate therapy and clinical outcome could be
observed; this is possibly due the relatively small pa-
tient number. This is an important limitation of the
present trial.
DTC and microenvironment
Despite progress made in the therapy of breast cancer,
the prognosis of patients even with small tumor burden
is still limited by metastatic relapse often long after re-
moval of the tumor. Current theories on biology of can-
cer suggest that disseminated tumor cells detected in
bone marrow or blood circulation of patients may serve
as a surrogate parameter for minimal residual diseaseTable 2 Survival analysis of 86 patients depending on
intravenous administration of zoledronic acid
ZOL group n (%) Control group n (%)
Total 40 (100%) 46 (100%)
Deaths 1 (2%) 5 (11%)
Relapses 1 3 (8%) 7 (15%)
Distant metastasis 3 (8%) 5 (11%)
Local recurrence 1 (2%) 4 (9%)
1 including local recurrence and distant metastases.and are therefore precursor of metastasis. However, it is
currently not predictable which of these cells will evolve
into metastases; presumably, the vast majority undergo
apoptosis leaving only a minor percentage able to persist
in secondary homing sites [15]. This phenomenon, de-
scribed as “metastatic inefficiency”, is consistent with the
observation that detection of tumor cells in blood or
bone marrow does not inevitably cause metastasis; 50%
of initially DTC-positive patients do not suffer from a
relapse and stay disease-free [1]. Studies suggest that
0.01% of CTC can ultimately produce a single bone me-
tastasis, and at least 10,000 CTC are required for the de-
velopment of a metastatic colony [16,17]. Nonetheless,
approximately one-third of patients fail to clear tumor
cells from the blood following removal of primary tumor
[18,19]. It is not yet clear, which factors determine the
fate of DTC and facilitate their persistence. Recently, on-
cologic research has focused increasingly not only on
the cancer cell itself but on its microenvironment; in this
context the concept of a premetastatic niche, permissive
to development of (micro-)metastases, has gained much
interest [20]. Bone tissue may serve as a suitable micro-
environment for the growth of tumor cells derived from
the primary tumor in the breast; it represents a dynamic
‘habitat’ influenced by a number of parameters, among them
angiogenetic mechanisms, osteoclastic bone resorption and
Figure 2 Survival analysis. ZOL group – patients assigned to
adjuvant therapy plus intravenous zoledronic acid every four weeks.
Control group – patients assigned to adjuvant therapy alone (a)
Overall survival (b) Relapse-free survival.
Table 3 Incidence of persistent disseminated tumor cells





Second BM aspiration performed
after 12 months
34 (100%) 37 (100%)
DTC detected after 12 months 4 (12%) 10 (27%)
Third BM aspiration performed
after 24 months
27 (100%) 32 (100%)
DTC detected after 24 months 0 (0%) 5 (16%)
Figure 3 Overall survival analysis with regard to detection of
persistent disseminated tumor cells at 12 months after diagnosis.
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ters leads to decreased bone density and osteoporosis; these
changes may affect the role of bone marrow as a homing
site for DTC. Consequently, bone-targeted agents, such as
BP, have not only a stabilizing effect on the bone density it-
self, but show antitumorigenic activity as well.
Antitumorigenic effects of bisphosphonates
There is a growing body of evidence of bisphosphonates’
anti-cancer activity in vivo and in vitro. BP are assumed
to alter bone and BM microenvironment affecting itsability to host tumor cells; their effect in the bone is
mainly due to inhibition of osteoclast-mediated bone
resorption [22]. Several preclinical and animal model-
based studies have demonstrated BP to exert direct
anti-cancer activity, inhibiting tumor cell adhesion
[23], invasion [24], proliferation and angiogenesis [25]
and inducing apoptosis [26,27]. Exposure of cortical
bone slices to BP partially inhibited breast cancer cell
adhesion in vitro [23]; interestingly, cancer cells appeared
to be more susceptible to BP treatment than normal cells
[28]. Boissier et al. demonstrated BP to inhibit breast can-
cer cell invasion in a dose-dependent manner using a
matrigel invasion assay. This effect was partly due to
observed reduction in proteolytic activity of matrix
metalloproteinases (necessary to digest basement mem-
brane). In that study, ZOL had the highest potency with
regard to invasion inhibition, followed by ibandronate,
risedronate analogue NE-10244 and clodronate [24].
Wood et al. showed significant antiangiogenic proper-
ties of zoledronate in vitro and in vivo [25]. Further,
Figure 4 Proportion of patients with DTC-positive bone
marrow at 12 and 24 months after diagnosis.
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inhibit the proliferation of human cancer cell lines and
induce their apoptosis [26]. Data from animal studies
confirm that BP exert potent effects on visceral metas-
tases as well [27,29]. These reports suggest that BP
affect the invasive behavior of metastatic cells in sec-
ondary sites through both direct and indirect effects
and have the ability to interact with tumor cells at each
step of the metastatic process.
Clinical relevance of bisphosphonate treatment in
adjuvant setting
The presence of DTC correlates significantly with in-
creased risks of distant metastasis, locoregional recurrence,
and death in breast cancer patients [1,30]. Therefore, treat-
ment strategies that target DTC in BM may potentially im-
prove disease-free and overall survival. We hypothesize
that bisphosphonates affect the role of bone marrow as a
suitable microenvironment for DTCs. Indeed, protective
effects of bisphosphonates were reported in clinical trials
exploring ZOL as adjuvant therapy in early breast cancer.
Three large prospective studies evaluated the impact
of addition of ZOL to systemic treatment on survival
(Table 4) [6,8,31]. The randomized open-label Austrian
Breast and Colorectal Cancer Study Group (ABCSG)-12
trial (NCT00295646) evaluated the influence of adding
ZOL to adjuvant endocrine therapy [31]. In this four-
arm trial, 1,803 premenopausal women with hormone
receptor positive early stage (stage I-II) breast cancer
were randomized to receive goserelin 3.6 mg every 28
days plus either tamoxifen 20 mg daily or anastrozole 1
mg daily, with or without ZOL 4 mg every 6 months for
3 years. At a median follow-up of 62 months, the addition
of ZOL reduced risk of disease-free survival events com-
pared with endocrine therapy alone (p = 0.009). The re-
duction in recurrence was observed locally and distantlyboth in and outside the bone. The risk of death was also
reduced but did not reach statistical significance, although
it approached significance in women older than 40 years
(p = 0.057).
In the Zometa-Femara Adjuvant Synergy Trials (Z-FAST/
ZO-FAST/E-ZO-FAST), designed to investigate the bone-
protective effects of zoledronic acid, an exploratory analysis
was conducted to assess the anticancer potential of
zoledronic acid. A total of 2,194 postmenopausal women
with hormoneresponsive early breast cancer received
letrozole 2.5 mg daily [6]. Patients were randomized to
receive zoledronic acid 4 mg administered every 6 months
for 5 years starting either upon randomization (up-front)
or upon a predetermined measure of bone loss (delayed
start). After 36 months of follow-up, a 34% reduced inci-
dence of disease-free survival (DFS) events with up-front
zoledronic acid treatment compared with delayed treat-
ment was observed in the ZO-FAST trial (P = 0.0375).
These studies show a DFS benefit or overall survival (OS)
benefit in postmenopausal women or women who have
chemical ovarian suppression.
In contrast to ABCSG-12 and ZO-FAST trials, the
Adjuvant Zoledronic Acid to Reduce Recurrence (AZURE;
BIG 01/04) trial (NCT00072020) did not show a benefit
from adding bisphosphonates to adjuvant therapy in the
overall patient population. The AZURE trial evaluated the
antitumor activity of ZOL combined with (neo)adjuvant
chemotherapy as well as endocrine therapy in 3,360 pre-
and postmenopausal patients with stage II/III breast
cancer [4]. Patients were randomly assigned to receive
standard adjuvant systemic therapy either with or without
ZOL (every 3–4 weeks for 6 doses and then every 3 to 6
months to complete 5 years of treatment). In a second in-
terim analysis, ZOL was not associated with a significant
improvement in DFS in the overall population. However, in
a subgroup analysis, ZOL improved OS by 29% (p = 0.017)
and reduced DFS events in and outside the bone in women
who were more than 5 years postmenopausal [8]. Interest-
ingly, in the subset of 195 patients who received neoadjuvant
chemotherapy addition of ZOL to neoadjuvant chemother-
apy reduced mean residual invasive tumor size by approxi-
mately 43% compared with chemotherapy alone. The
adjusted mean residuum was 12 mm lower in the ZOL
group (15.5 mm) than in the group not receiving ZOL
(27.4 mm; p = 0.006), suggesting potential antitumor
benefit from combining bisphosphonates with cyto-
toxic treatment [8].
Further, Aft et al. [14] demonstrated that DTC-free BC
patients treated with ZOL (4 mg every 3 weeks) were
more likely to remain DTC free at 3 months (P = 0.03),
and that the subset of patients with estrogen receptor-
negative and epidermal growth factor receptor-2–negative
disease were more likely to have pathologic complete re-
sponse with ZOL versus no ZOL. In small studies, ZOL
Table 4 Studies evaluating antitumor activity of bisphosphonates in breast cancer
Study/clinical
trial
ZO-FAST ABCSG-12 GAIN NSABP-B34 AZURE Saarto [32] Diel [33] Kristensen [34] Powles [35]
N 1065 1803 3023 3323 3360 299 302 953 1069
Bisphosphonate Zoledronate i.v. Zoledronate i.v. Ibandronate p.o. Clodronate p.o. Zoledronate i.v. Clodronate p.o. Clodronate p.o. Pamidronate p.o. Clodronate p.o.
Duration of
therapy
5 years 3 years 2 years 3 years 5 years 3 years 2 years 4 years 2 years




CTX +/- Endocrine CTX +/- Endocrine CTX +/- Endocrine CTX +/- Endocrine CTX CTX +/- Endocrine
Follow up 60 months 84 months 39 months 91 months 60 months 120 months 103 months n.d. 66 months
Premenopausal - Yes (DFS, OS) No No No No Yes (OS) No Yes (OS, bonemetastasis
free survival)
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patients who remained DTC-free at 6 months versus
no ZOL [36], and significantly decreased DTC levels versus
baseline at 12 (P < 0.0006) and 24 months (P = 0.0026)
[37] in DTC-positive BC patients. Therefore, it is rea-
sonable to hypothesize that ZOL may delay disease
recurrence.
Extensive data on the adjuvant effects of another
bisphosphonate, clodronate, were provided by Diel et al. [33].
In that prospective clinical trial 302 patients were ran-
domized to receive either oral clodronate 1600 mg/day for
2 years or standard follow-up. An updated survival ana-
lysis with a median follow-up of 103 months showed pa-
tients in clodronate group to perform better with regard
to OS (p = 0.049).
Conclusions
Our data confirm the antitumor properties of zoledronate
demonstrated in numerous preclinical studies. ZOL treat-
ment effectively eliminated DTC; patients with persistent
tumor cells in BM had significantly worse survival. The
ability of ZOL to target minimal residual disease may have
significant implications for long-term clinical outcome.
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